List view / Grid view
20 August 2020 | By SUEZ
The new Sievers Eclipse Bacterial Endotoxins Testing (BET) Platform combines ground-breaking technology and ease-of-use to automate endotoxin assay setup without altering reaction biochemistry or compliance. Watch our on-demand webinar to learn more.
Moderna will supply the US with at least 100 million doses of mRNA-1273, its COVID-19 vaccine candidate currently in Phase III clinical trials.
An agreement between AstraZeneca and the European Commission means the company will supply up to 400 million doses of its AZD1222 COVID-19 vaccine.
Grant Courtney explains why traceability is vital for the current pandemic as it would guarantee that COVID-19 vaccines are safe, effective and suitably distributed.
The 'One Million Post-Authorisation Study' has been established to monitor the safety and effectiveness of COVID-19 vaccines in real-life conditions.
The International Air Cargo Association and Pharma.Aero will form a joint working group to provide air cargo guidance to the logistics industry for the transportation of COVID-19 vaccines.
A COVID-19 vaccine dubbed “Sputnik V” has been given regulatory approval in Russia, before completing its clinical trials.
A new report has outlined that AstraZeneca has been granted protection from product liability claims regarding its COVID-19 vaccine candidate.
A new vaccine platform using self-assembling peptide nanofibres tagged with antigens has been tested successfully in mice, eliciting a strong immune response.
J&J will supply the US with 100 million doses of the company’s COVID-19 vaccine candidate following an agreement with the country's government.
A Phase I trial conducted by Novavax to test NVX‑CoV2373, the company’s recombinant COVID-19 vaccine candidate, showed it elicited robust antibody responses.
RNAdvance Viral Kits. High-quality RNA extraction from saliva or swab transport media. Automation ready. LoD demonstrated at 1 copy/μL.
A DNDi-commissioned report on the Malaysian reaction to COVID-19 has revealed the strengths and weaknesses of the country’s response.
The UK government reserved a production line at Wockhardt for 18 months to ensure the rapid fill finish of COVID-19 vaccines.
The first patients have been dosed in Moderna's Phase III clinical trial of its mRNA vaccine candidate to protect against COVID-19.
